TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07288554: A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Health

Sponsor: Bambusa Therapeutics · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 68 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,105,500

Rescue Site Savings

+$2,721,360

Unlock Full NCT07288554 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07288554 Rescue Dossier →